ArticleHereditas2025
Unraveling lncRNA TRG-AS1: a novel biomarker for poor prognosis of gastric cancer and key to regulating malignant behaviors by targeting miR-873-5p.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The highly expressed lncRNA TRG-AS1 in serum specifically inhibits miR-139-5p, thereby promoting oxidative stress and inflammation in heart failure.Journal of cardiothoracic surgery · 2026Article
- Long non-coding RNA SOCS2-AS1 inhibits gastric cancer progression via the miR-324-3p/GRIK3 axis: a mechanistic study.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimsTo alleviate patient stress and advance gastric cancer research, this study aims to investigate the potential association between aberrant expression of TRG-AS1 and gastric cancer, and to examine its potential impact on the biological behaviors of gastric cancer cells. MATERIALS AND
methodsTo find out how TRG-AS1 is expressed in the tissues and cells of gastric cancer, real-time fluorescence quantitative PCR was employed. The connection between TRG-AS1 and pathological features, as well as its prognostic importance, were examined using the Chi-square test and Cox regression analysis. The dual luciferase reporting assay was utilized to confirm the targeting of TRG-AS1 and miR-873-5p. Transwell assay and CCK-8 test were used to identify the roles that TRG-AS1 plays in cell metastasis and proliferation, respectively.
resultsResearch has revealed a downregulation of TRG-AS1 in the tissues and cells, which is strongly correlated with the differentiation, TNM stage, lymph node metastasis, depth of invasion, and patient survival rate in gastric cancer. The binding sites exists between miR-873-5p and TRG-AS1, and TRG-AS1 has the ability to negatively control miR-873-5p by acting as a competitive endogenous RNA. When TRG-AS1 was overexpressed, the malignant behavioral activity of gastric cancer cells was significantly decreased; however, the inhibitory effect was reversed when miR-873-5p was overexpressed.
conclusionsTRG-AS1 is a potential predictor of poor prognosis in gastric cancer patients and targets miR-873-5p to inhibit the progression of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.